Page last updated: 2024-08-23

oltipraz and Fatty Liver

oltipraz has been researched along with Fatty Liver in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's4 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lin, J; Wang, SY1
Kim, W; Kim, YJ1
Chang, MS; Cho, JY; Kim, BG; Kim, H; Kim, JH; Kim, SG; Kim, W; Kim, YJ; Lee, CK; Lee, J; Lee, JH; Lee, JS; Yeon, JE; Yi, S1
Bae, EJ; Hwahng, SH; Ki, SH; Kim, HE; Kim, SG1
Brooks, JS; Brooks, SC; Kim, SG; Lee, MG; Lee, WH1
Eom, JS; Kim, SG; Kim, TH; Lee, CG; Lee, YS; Yang, YM1

Reviews

1 review(s) available for oltipraz and Fatty Liver

ArticleYear
Therapeutic potential of dithiolethiones for hepatic diseases.
    Pharmacology & therapeutics, 2009, Volume: 124, Issue:1

    Topics: Animals; CCAAT-Enhancer-Binding Protein-beta; Fatty Liver; Glutathione Transferase; Humans; Inactivation, Metabolic; Insulin Resistance; Liver; Liver Cirrhosis; Liver Diseases; MAP Kinase Signaling System; Phosphatidylinositol 3-Kinases; Protein Kinases; Pyrazines; Receptors, Aryl Hydrocarbon; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Thiones; Thiophenes; TOR Serine-Threonine Kinases

2009

Trials

1 trial(s) available for oltipraz and Fatty Liver

ArticleYear
Randomised clinical trial: the efficacy and safety of oltipraz, a liver X receptor alpha-inhibitory dithiolethione in patients with non-alcoholic fatty liver disease.
    Alimentary pharmacology & therapeutics, 2017, Volume: 45, Issue:8

    Topics: Adult; Animals; Double-Blind Method; Fatty Liver; Female; Humans; Liver X Receptors; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Mice; Middle Aged; Non-alcoholic Fatty Liver Disease; Pyrazines; Thiones; Thiophenes; Treatment Outcome; Ultrasonography

2017

Other Studies

4 other study(ies) available for oltipraz and Fatty Liver

ArticleYear
Letter: the efficacy of oltipraz in patients with non-alcoholic fatty liver disease has not been confirmed.
    Alimentary pharmacology & therapeutics, 2017, Volume: 46, Issue:2

    Topics: Fatty Liver; Humans; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Pyrazines; Thiones; Thiophenes

2017
Letter: the efficacy of oltipraz in patients with non-alcoholic fatty liver disease has not been confirmed-authors' reply.
    Alimentary pharmacology & therapeutics, 2017, Volume: 46, Issue:2

    Topics: Fatty Liver; Humans; Non-alcoholic Fatty Liver Disease; Pyrazines; Thiones; Thiophenes

2017
Role of adenosine monophosphate-activated protein kinase-p70 ribosomal S6 kinase-1 pathway in repression of liver X receptor-alpha-dependent lipogenic gene induction and hepatic steatosis by a novel class of dithiolethiones.
    Hepatology (Baltimore, Md.), 2009, Volume: 49, Issue:6

    Topics: Animals; Cyclic AMP-Dependent Protein Kinases; DNA-Binding Proteins; Fatty Liver; Liver X Receptors; Male; Mice; Mice, Inbred C57BL; Orphan Nuclear Receptors; Pyrazines; Receptors, Cytoplasmic and Nuclear; Ribosomal Protein S6 Kinases, 70-kDa; Sterol Regulatory Element Binding Protein 1; Thiones; Thiophenes; Transcriptional Activation

2009
An active metabolite of oltipraz (M2) increases mitochondrial fuel oxidation and inhibits lipogenesis in the liver by dually activating AMPK.
    British journal of pharmacology, 2013, Volume: 168, Issue:7

    Topics: AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents; Anticarcinogenic Agents; Antioxidants; Diet, High-Fat; Enzyme Activation; Fatty Liver; Hep G2 Cells; Humans; Lipid Metabolism; Lipogenesis; Liver; Liver X Receptors; Male; Mice; Mice, Inbred C57BL; Mitochondria; Orphan Nuclear Receptors; Oxidation-Reduction; Oxidative Stress; Pyrazines; Sterol Regulatory Element Binding Protein 1; Thiones; Thiophenes

2013